Actinogen Medical Limited ATGGF
0.33 USD 0.00 (+0.00%)
Regular-session close
0.25 Day range 0.25
0.0008 52-week range 0.33
- YTD
- +725.00%
- 1 year
- +725.00%
News
proactiveinvestors.com Actinogen Medical highlights Xanamem potential in older Alzheimer's patients - ICYMI Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week reported encouraging results among older Alzheimer's disease patients in its XanaMIA clinical trial, with CEO Dr Steven Gourlay outlining…
seekingalpha.com Actinogen Medical Limited (ATGGF) Discusses Xanamem Trial Results in Older Patients With Alzheimer's Disease Transcript Actinogen Medical Limited (ATGGF) Discusses Xanamem Trial Results in Older Patients With Alzheimer's Disease Transcript
proactiveinvestors.com Actinogen Medical nears key XanaMIA trial readout - ICYMI Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week highlighted progress towards the November topline readout from its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, with the final…
proactiveinvestors.com Actinogen Medical enters ‘database lock' to process XanaMIA' data and confirm findings The results for Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF)'s latest Alzheimers disease trial, ‘XanaMIA' are set to be released in mid-November. With final patient visits completed, the company…
proactiveinvestors.com Actinogen Medical closes September quarter with XanaMIA readout in sight Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) closed the September quarter with its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial on track for topline results in November and a pro-forma cash…
proactiveinvestors.com Actinogen's Xanamem trial hits key milestone ahead of results - ICYMI Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, putting the company on course to report…
proactiveinvestors.com Actinogen Medical completes final XanaMIA patient visit; November Alzheimer's trial results on track Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, keeping topline results from the closely watched study on…
proactiveinvestors.com Dow slips, Nasdaq edges lower as August ends in green 4:30pm: Wall Street caps winning month Wall Street closed lower on Monday, but the major indexes still wrapped up a winning August as investors look ahead...
proactiveinvestors.com Nvidia's $12.9bn Hugging Face swoop is really about filling the cloud capacity it has underwritten The price Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) is reported to be paying is the first thing analysts have flagged, and on the face of it $12.9 billion for...
proactiveinvestors.com UBS says bond market relief from falling yields will not offset deeper structural pressures UBS has said recent falls in bond yields and oil prices offer only temporary relief, with structural forces likely to keep long-term borrowing costs high,...
proactiveinvestors.com Riot Platforms $9.1B AI deal fuels speculation around Anthropic IPO Riot Platforms Inc (NASDAQ:RIOT) shares rose about 4% on Tuesday after the bitcoin mining company announced a 20-year data center lease with a leading...
proactiveinvestors.com Traders see little chance of Hormuz shipping recovery by end of August Prediction market traders have cut the odds of a meaningful recovery in shipping through the Strait of Hormuz by the end of this month, despite renewed talk...
proactiveinvestors.com Hikma jumps 10% as brokers point to profit beat and undemanding rating Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel...
proactiveinvestors.com Actinogen Medical outlines scientific case for Xanamem in Alzheimer’s disease ahead of pivotal trial results Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has outlined the scientific rationale supporting its lead drug candidate Xanamem® (emestedastat) as a potential...
proactiveinvestors.com The Small Cap Watch: Healthcare, critical minerals and gold explorers advance projects The S&P/ASX Small Ordinaries Index (ASX) closed at 3,482.30 on Wednesday, August 5, gaining 80.50 points or 2.37%. The index has risen 170.20 points, or...
proactiveinvestors.com Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week reported continued progress across its clinical, regulatory and financial programs during the...
proactiveinvestors.com Novo Resources expands Wyloo silver targets - ICYMI Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO, FRA:1NOR) earlier this week confirmed that maiden reverse circulation drilling at its Wyloo Polymetallic...
proactiveinvestors.com Horizon Gold details A$1.31B Gum Creek NPV - ICYMI Horizon Gold Ltd (ASX:HRN, OTC:HZGLF, FRA:HO0) earlier this week confirmed a financially robust development pathway for its 100%-owned Gum Creek Gold...
proactiveinvestors.com Resolution Minerals secures second FAST-41 status - ICYMI Resolution Minerals Ltd (ASX:RML, OTCQB:RLMLF, FRA:NC3) earlier this week secured US Federal FAST-41 Transparency coverage for its Golden Gate tungsten-gold...
proactiveinvestors.com Actinogen Medical’s Xanamem shows meaningful antidepressant activity in Phase 2 trial Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) this week reported encouraging evidence that its lead drug candidate Xanamem® (emestedastat) may offer a novel...
